[
  {
    "ts": null,
    "headline": "How Positive Phase 3 Cemdisiran Results at Regeneron (REGN) Have Changed Its Investment Story",
    "summary": "In August 2025, Regeneron Pharmaceuticals announced that its investigational siRNA therapeutic cemdisiran met both primary and key secondary endpoints in a Phase 3 trial for adults with generalized myasthenia gravis, highlighting clinical progress in its rare disease pipeline. This advance underscores Regeneron's momentum in developing next-generation treatments, adding to recent strong performances of core products and reflecting robust clinical execution. We'll examine how positive Phase 3...",
    "url": "https://finnhub.io/api/news?id=ba2933debdecd7744a28b36157c26c2281b11ac854713b9d1b458c3696c7075d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757161787,
      "headline": "How Positive Phase 3 Cemdisiran Results at Regeneron (REGN) Have Changed Its Investment Story",
      "id": 136669513,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "In August 2025, Regeneron Pharmaceuticals announced that its investigational siRNA therapeutic cemdisiran met both primary and key secondary endpoints in a Phase 3 trial for adults with generalized myasthenia gravis, highlighting clinical progress in its rare disease pipeline. This advance underscores Regeneron's momentum in developing next-generation treatments, adding to recent strong performances of core products and reflecting robust clinical execution. We'll examine how positive Phase 3...",
      "url": "https://finnhub.io/api/news?id=ba2933debdecd7744a28b36157c26c2281b11ac854713b9d1b458c3696c7075d"
    }
  }
]